Feed / SIBN

SI-BONE, Inc.

SIBN

Healthcare · 18.36 +0.4% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

SI-BONE, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 11 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.

Company+0.4% todayVolume comparison unavailable
Market group0 of 11 activeUtilities and REITs · unavailable
Disclosed network0 of 4 confirmingNo filing-linked name is confirming now
What would change this read
  • SIBN's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if SIBN's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Medical Devices

No new filing conclusion is available. 0 of 11 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • SIBN's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods9
Price observations320
Usable filing statements79
Verified relationships4
Evidence supporting the case
  • Latest annual revenue changed +20.2% year over year.
  • Operating margin changed +10.0 percentage points in the latest annual period.
  • Net margin changed +9.1 percentage points in the latest annual period.
Evidence challenging the case
  • Diluted shares increased 3.6% in the latest annual period.
  • Credit and interest rates has repeated adverse evidence across 4 filings.
Questions before a position
  • EV/sales is 23% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 11, 2026

18.36
6m+16.9%12m+10.5%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2021-12-31$90.2M+22.8%$-1.71+14.1%
2022-12-31$106.4M+18.0%$-1.79+3.2%
2023-12-31$138.9M+30.5%$-1.13+12.4%
2024-12-31$167.2M+20.4%$-0.75+7.9%
2025-12-31$200.9M+20.2%$-0.44+3.6%

What management says matters

Persistent and emerging business drivers

Credit and interest ratesnegative · 4 filings
The decrease in interest expense for the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 was primarily due to lower interest rates associated with the First-Citizens Fourth Amended Loan Agreement.
10-Q · May 11, 2026
Foreign exchangemixed · 4 filings
Our revenue from international sales is impacted by fluctuations in foreign currency exchange rates between the U.S.
10-Q · May 11, 2026
Product pipeline and R&Dmixed · 4 filings
Significant changes in net operating assets during the three months ended March 31, 2026 included higher inventory levels to support new product introductions, higher accounts receivable due to timing of sales and cash collections, and lower accrued liabiliti…
10-Q · May 11, 2026
Legal and regulatory exposurenegative · 1 filings
The decrease in research and development expenses for the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 was due to timing and stage of product development across projects, as we continue to invest in recently launched…
10-Q · May 11, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 3.9× · EV/sales 3.9×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

18.36+0.4% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for SIBN. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for SIBN. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind SIBN

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ATECAlphatec Holdings, Inc.competitorFeb 24, 2026

We believe that our primary competitors marketing implantable devices currently are Alphatec Holding Inc., Aurora Spine Corporation, Globus Medical, Inc., Medtronic plc., and Tenon Medical, Inc.

GMEDGlobus Medical, Inc.competitorFeb 24, 2026

We believe that our primary competitors marketing implantable devices currently are Alphatec Holding Inc., Aurora Spine Corporation, Globus Medical, Inc., Medtronic plc., and Tenon Medical, Inc.

MDTMedtronic plccompetitorFeb 24, 2026

We believe that our primary competitors marketing implantable devices currently are Alphatec Holding Inc., Aurora Spine Corporation, Globus Medical, Inc., Medtronic plc., and Tenon Medical, Inc.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 6 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

SIBN is currently a Follower in the organic co-movement group Utilities and REITs. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for SIBN; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.